asa statement on glp 1 The 2023 position GLP-1 receptor agonists has been overturned by three 2025 consensus statements. Continue the drug. Change the fast. ANZCA/ADS/GESA/NACOS, the Association of Anaesthetists/RCoA, and SPAQI/AACE now converge on GLP-1 and Anesthesia: Considerations and

doi: 10.1161/JAHA.119.012244

Ellingsgaard H, Hauselmann I, Schuler B, et al

Compounding Options & Delivery Forms Compounded weight management therapies can be prepared in a variety of dosage forms based on a licensed providers prescription and a patients specific needs

Overall, the evidence suggests that the opposing effects of ghrelin and GLP-1 on mediating GI-associated malaise may be a driving component of their opposing effects on food reward-motivated behaviors

Incretin-based therapies are increasingly recognized not only for their weight-loss effects but also for their broader health benefits

For Ozempic or Wegovy, the window is generally five days